Related references
Note: Only part of the references are listed.Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor-Deficient Mice
Frederique Dol-Gleizes et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Does reversal of oxidative stress and inflammation provide vascular protection?
Kwang Kon Koh et al.
CARDIOVASCULAR RESEARCH (2009)
Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages
Li-sheng Jiang et al.
CARDIOVASCULAR RESEARCH (2009)
CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages
Ki Hoon Han et al.
CARDIOVASCULAR RESEARCH (2009)
The Cannabinoid Receptor 2 Is Critical for the Host Response to Sepsis
Johannes Tschoep et al.
JOURNAL OF IMMUNOLOGY (2009)
Targeting the endocannabinoid system: to enhance or reduce?
Vincenzo Di Marzo
NATURE REVIEWS DRUG DISCOVERY (2008)
The complications of promiscuity: endocannabinoid action and metabolism
S. P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
S Steffens et al.
NATURE (2005)
The cannabinoid system and immune modulation
TW Klein et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Share Paper
